Source: Medical Device Business Review

On December 8, 2025, Medtronic announced a key personnel appointment: Ms. Ingrid Goldberg officially joined the company as Vice President and Head of Investor Relations. This appointment coincides with the strategic restructuring of the company’s Diabetes Business Unit, which is being spun off into a standalone entity named MiniMed.

Ryan Weispfenning (left) will depart from his current role to lead investor relations at MiniMed, a subsidiary of Medtronic.Ingrid Goldberg (right) is Medtronic’s new Head of Investor Relations.

Ms. Goldberg has officially assumed her role at Medtronic with immediate effect. Boasting over 20 years of industry experience, her career spans the financial, medical device, and life sciences sectors.

Most recently, Goldberg served as Vice President of Finance and Investor Relations at Novocure, where she oversaw investor relations, communications, and business development initiatives. Prior to joining Novocure, she held various leadership positions at Abiomed, now a part of Johnson & Johnson MedTech.

Medtronic noted that Goldberg led the investor relations department at Abiomed during a period of substantial expansion. She also previously headed investor relations at Bluebird Bio, a developer of gene and cell therapies. Before entering the healthcare industry, Goldberg spent a decade at Bank of America Merrill Lynch.

Commenting on her appointment, Goldberg stated, "Medtronic improves patients’ lives through tangible actions every single day, and its product portfolio is extremely compelling. I am eager to share the company’s innovative progress with the world and contribute to an organization dedicated to advancing human health."

Against the backdrop of this personnel reshuffle, Ryan Weispfenning, the former Head of Investor Relations, will transition to a new role, focusing on leading investor relations for MiniMed as it prepares for its spinoff from Medtronic to become an independent company.

With more than 25 years of experience at Medtronic, Weispfenning has led the investor relations team for over a decade. The company recognizes him as a key figure instrumental in forging strong relationships with global investors and analysts.

Medtronic anticipates that his expertise will play a pivotal role in MiniMed’s spinoff process. Weispfenning commented, "For the past decade, I have led investor relations at Medtronic. Now, I am honored to help establish an independent investor relations function for MiniMed and articulate to investors its long-term strategy and growth commitments as a publicly traded standalone company."

To ensure operational continuity, Medtronic stated that Ryan Weispfenning will support the newly appointed Head Ingrid Goldberg and her team for a transitional period to facilitate a seamless handover.